Keith Orford is Director at Calithera Biosciences, Inc. (CALA). They have made 2 open-market trades across 1 company since 2017, most recently 2021-11-11.
CIK 0001670740
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CALA | 66,094 | $215K |
Shares reported on the most recent Form 4, priced at the 2021-11-12 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CALA | SELL | 2021-11-10 | 2021-11-12 | $0.87 | $68K | -14.2% | -27.6% | -52.4% |
| CALA | SELL | 2021-11-09 | 2021-11-09 | $0.84 | $44K | +11.4% | -2.2% | -33.8% |
| CALA | SELL · 10b5-1 | 2020-12-16 | 2020-12-18 | $6.00 | $15K | -4.7% | -39.8% | -46.8% |
| CALA | SELL · 10b5-1 | 2020-02-20 | 2020-02-24 | $8.00 | $24K | -12.4% | -44.0% | -18.5% |
| CALA | SELL · 10b5-1 | 2019-12-23 | 2019-12-26 | $6.00 | $18K | -15.2% | +10.6% | -31.9% |
| CALA | SELL · 10b5-1 | 2019-06-17 | 2019-06-19 | $6.00 | $3K | -5.5% | -2.1% | -5.0% |
| CALA | SELL · 10b5-1 | 2019-05-22 | 2019-05-24 | $6.00 | $2K | -7.9% | -31.9% | -32.5% |
| CALA | SELL · 10b5-1 | 2019-04-15 | 2019-04-17 | $6.33 | $3K | +1.8% | -6.8% | -27.9% |
| CALA | SELL · 10b5-1 | 2019-03-15 | 2019-03-19 | $6.43 | $3K | +4.0% | -4.9% | -10.5% |
| CALA | SELL · 10b5-1 | 2019-03-11 | 2019-03-13 | $6.00 | $9K | -0.2% | -0.9% | -19.4% |
| CALA | SELL · 10b5-1 | 2018-10-15 | 2018-10-17 | $6.05 | $2K | -13.9% | -11.0% | -26.3% |
| CALA | SELL · 10b5-1 | 2018-10-11 | 2018-10-15 | $6.00 | $8K | -12.2% | -16.0% | -28.1% |
| CALA | SELL · 10b5-1 | 2017-07-17 | 2017-07-19 | $18.31 | $39K | -6.7% | -14.6% | +8.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.